Mirna Therapeutics
08-31-16

Mirna Therapeutics to Participate in Two Healthcare Investor Conferences in September

AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical stage biopharmaceutical company developing a pipeline of microRNA-based oncology therapeutics, today announced that senior management will participate in two upcoming healthcare investor conferences in September.

Conference Details:

Event: Citi's 11th Annual Biotech Conference
Date: September 7-8, 2016
Location: Boston, MA

Event: Rodman & Renshaw 18th Annual Global Investment Conference
Date/Time: Tuesday, September 13, 2016 at 10:25 a.m. ET
Location: New York, NY

The Rodman & Renshaw presentation will be webcast live and may be accessed from the Events & Presentations section of the Mirna Therapeutics website. An archived version of the webcast will be available for replay following the event.

About Mirna Therapeutics, Inc.

Mirna is a clinical stage biopharmaceutical company developing a pipeline of microRNA-based oncology therapeutics and is the first to bring a synthetic microRNA mimic into clinical development for the treatment of cancer. Mirna's lead product candidate, MRX34, a mimic of naturally occurring microRNA-34 (miR-34), is being studied in a Phase 1 clinical trial which has included patients with primary liver cancer, advanced solid tumors and hematological malignancies. miR-34 is one of the most widely published microRNAs and is considered a key regulator of multiple oncogenes across key oncogenic pathways, with the capacity to regulate more than 30 different oncogenes and repress immune checkpoint signaling molecules, including PD-L1. The potential capacity to simultaneously affect multiple pathways and processes that are critical to cancer cell viability may make mimics of tumor suppressor microRNAs an important new class of anti-cancer agents. Mirna plans to develop MRX34 as a monotherapy and in combination with other therapies. The Company was founded in 2007 and is located in Austin, Texas.

For more information, visit www.mirnarx.com.

Investors
The Trout Group
Pete Rahmer, 646-378-2973
prahmer@troutgroup.com
or
Media
BMC Communications
Amy Bonanno, 646-513-3117
abonanno@bmccommunications.com

Source: Mirna Therapeutics, Inc.

News Provided by Acquire Media